Healthcare / Pharmaceutical RetailersTokyo
$1637.00
-41.00 (-2.44%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $232.0M · quality 39.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$31.8B
P/E
7.9x
↓EV/EBITDA
6.3x
↓ROE
10.0%
↑Gross Margin
21.5%
↓Debt/Equity
0.86
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+8.3%
FCF CAGR
—
FCF margin
-5.5%
FCF / Net income
-2.22x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $163.81B · net income $4.03B · FCF $-8.93B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $163.81B | $163.81B | $151.96B | $142.24B | $128.79B |
| Net Income | $4.03B | $4.03B | $4.28B | $3.83B | $3.24B |
| EBITDA | $8.97B | $8.97B | $8.71B | $8.16B | $7.56B |
| EPS | — | — | — | 195.22 | 164.96 |
| Gross Margin | 21.5% | 21.5% | 21.5% | 21.6% | 21.9% |
| Operating Margin | 3.2% | 3.2% | 3.6% | 3.7% | 3.6% |
| Net Margin | 2.5% | 2.5% | 2.8% | 2.7% | 2.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.86 | 0.86 | 0.49 | 0.41 | 0.53 |
| Current Ratio | 1.52 | 1.52 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-8.93B | $-8.93B | $232.0M | $3.47B | $2.70B |
| Returns | |||||
| ROE | 10.0% | 10.0% | 11.5% | 11.5% | 10.8% |
| Valuation | |||||
| P/E | 7.93 | 7.93 | — | 14.40 | 14.49 |
| EV/EBITDA | 6.29 | 6.29 | 5.40 | 7.81 | 7.59 |
| P/B | 0.79 | 0.79 | 0.97 | 1.65 | 1.57 |
| Growth & Yield | |||||
| Revenue Growth | 7.8% | 7.8% | 6.8% | 10.4% | — |
| EPS Growth | — | — | — | 18.3% | — |
| Dividend Yield | 1.8% | 1.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.9%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → n/d
Residual
-19.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.